Publication details

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

Authors

KISS David MACHÁČKOVÁ Táňa SOUČKOVÁ Kamila FABIAN Pavel KREPELKOVA I. SVOBODA M. KISS Igor

Year of publication 2021
Type Article in Periodical
Magazine / Source In vivo
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://iv.iiarjournals.org/content/35/5/2809
Doi http://dx.doi.org/10.21873/invivo.12567
Keywords Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation
Description Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info